Hidetoshi Igari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hidetoshi Igari has a total of 167 co-authors. Here are the top co-authors by number of shared publications:
- Toshibumi Taniguchi
Division of Infection Control, Chiba University, Chiba, Japan
13 shared publications - Misuzu Yahaba
Division of Infection Control, Chiba University Hospital, 1-8-1 Inohana Chuo-Ku, Chiba, 260-8677, Japan
10 shared publications - Shin Takayanagi
Division of Infection Control, Chiba University Hospital, 1-8-1 Inohana Chuo-Ku, Chiba, 260-8677, Japan
5 shared publications - Shingo Yamazaki
Division of Pharmacy Chiba University Hospital Chiba Japan
5 shared publications - Yohei Kawasaki
Department of Biostatistics, Graduate School of Medicine, Saitama Medical University, Saitama, Japan
5 shared publications - Eiji Ido
Department of Infectious Diseases, Chiba University Hospital, Chiba, Japan
4 shared publications
Latest Publications
- Open Access
Cost-Effectiveness of Ensitrelvir for COVID-19 Post-Exposure Prophylaxis Among High-Risk Household Contacts in Japan: A Model-Based Cost-Utility Analysis
Background: Ensitrelvir reduced symptomatic COVID-19 after household exposure in the SCORPIO-PEP trial, but its economic value as post-exposure prophylaxis is unknown. Objective: To estimate the cost-effectiveness of ensitrelvir post-exposure prophylaxis for high-risk household contacts in Japan. Methods: We developed a decision-analytic cost-utility model from the Japanese public healthcare payer perspective. Trial risks of symptomatic COVID-19 through day 10 were linked to Japanese evidence on hospitalization, mortality, costs, quality of life, and life expectancy. Because the trial observed no COVID-19-related hospitalization or death, downstream outcomes were modeled only through prevention of symptomatic disease. We performed deterministic, probabilistic, structural, subgroup, and threshold analyses. Results: Ensitrelvir increased costs by JPY 54,945 and gained 0.003267 QALYs per exposed contact, yielding an ICER of JPY 16.82 million/QALY. None of 10,000 simulations was cost-effective at JPY 5 million/QALY. Applying the overall-trial relative risk to the high-risk baseline yielded JPY 19.24 million/QALY. Restricting post-acute utility loss to 6 months, halving it, or excluding it yielded ICERs of JPY 23.62 million, JPY 26.76 million, and JPY 65.51 million/QALY, respectively. The drug acquisition-cost threshold was JPY 11,021 per course. Conclusions: At current Japanese costs, ensitrelvir post-exposure prophylaxis for high-risk household contacts was unlikely to be cost-effective at JPY 5 million/QALY. This conclusion remained unfavorable under conservative efficacy, post-acute utility, hospitalization-attribution, and mortality assumptions. Severe-outcome benefits remain model-based extrapolations rather than trial-observed effects. Key Points for Decision Makers: The pivotal post-exposure prophylaxis trial showed a substantial reduction in symptomatic COVID-19, but no COVID-19-related hospitalization or death occurred; modeled severe-outcome benefits therefore depend on external Japanese evidence. At current Japanese drug and delivery costs, the base-case ICER was JPY 16.82 million per QALY. The probability of cost-effectiveness was 0% at JPY 5 million per QALY and 2.28% at JPY 10 million per QALY. The acquisition-cost threshold was approximately JPY 11,000 per course. Conservative efficacy and post-acute utility scenarios remained above JPY 19 million and JPY 23 million per QALY, respectively.
Open AccessCost-Effectiveness of Ensitrelvir for COVID-19 Post-Exposure Prophylaxis Among High-Risk Household Contacts in Japan: A Model-Based Cost-Utility Analysis
Background: Ensitrelvir reduced symptomatic COVID-19 after household exposure in the SCORPIO-PEP trial, but its economic value as post-exposure prophylaxis is unknown. Objective: To estimate the cost-effectiveness of ensitrelvir post-exposure prophylaxis for high-risk household contacts in Japan. Methods: We developed a decision-analytic cost-utility model from the Japanese public healthcare payer perspective. Trial risks of symptomatic COVID-19 through day 10 were linked to Japanese evidence on hospitalization, mortality, costs, quality of life, and life expectancy. Because the trial observed no COVID-19-related hospitalization or death, downstream outcomes were modeled only through prevention of symptomatic disease. We performed deterministic, probabilistic, structural, subgroup, and threshold analyses. Results: Ensitrelvir increased costs by JPY 54,945 and gained 0.003267 QALYs per exposed contact, yielding an ICER of JPY 16.82 million/QALY. None of 10,000 simulations was cost-effective at JPY 5 million/QALY. Applying the overall-trial relative risk to the high-risk baseline yielded JPY 19.24 million/QALY. Restricting post-acute utility loss to 6 months, halving it, or excluding it yielded ICERs of JPY 23.62 million, JPY 26.76 million, and JPY 65.51 million/QALY, respectively. The drug acquisition-cost threshold was JPY 11,021 per course. Conclusions: At current Japanese costs, ensitrelvir post-exposure prophylaxis for high-risk household contacts was unlikely to be cost-effective at JPY 5 million/QALY. This conclusion remained unfavorable under conservative efficacy, post-acute utility, hospitalization-attribution, and mortality assumptions. Severe-outcome benefits remain model-based extrapolations rather than trial-observed effects. Key Points for Decision Makers: The pivotal post-exposure prophylaxis trial showed a substantial reduction in symptomatic COVID-19, but no COVID-19-related hospitalization or death occurred; modeled severe-outcome benefits therefore depend on external Japanese evidence. At current Japanese drug and delivery costs, the base-case ICER was JPY 16.82 million per QALY. The probability of cost-effectiveness was 0% at JPY 5 million per QALY and 2.28% at JPY 10 million per QALY. The acquisition-cost threshold was approximately JPY 11,000 per course. Conservative efficacy and post-acute utility scenarios remained above JPY 19 million and JPY 23 million per QALY, respectively.
- Open Access
- 5 February 2026
- Published by Microbiology Society in Journal of General Virology
- Vol. 107 (2) , 002215
Identification of an extremely large-scale genomic rearrangement in the Mpox virus while retaining replicative capacity
Understanding the genomic diversity of the Mpox (formerly known as ‘monkeypox’) virus (MPXV) is important for monitoring viral evolution and dissemination. We encountered three clinical cases in our hospital during the outbreak period of Mpox in 2023 in Japan. The present study aims to report the largest genomic rearrangement observed to date in one of the clinical isolates and to demonstrate its viability in cell culture. Whole-genome sequencing and digital PCR were used to characterize the viral genomes. Viral isolation, microscopic observation and growth kinetics in Vero cells were performed to confirm viral replication. All three patients were men living with human immunodeficiency virus (HIV) and presented typical Mpox symptoms, such as rash, fever and pustules on the body surfaces, including near the genitals. Virus isolation was successful in all three cases. All viral strains belonged to clade IIb, lineage C.1. Notably, one strain exhibited a large-scale genomic rearrangement: a 5.5 kb deletion at the left variable region replaced by a 30.5 kb inverted sequence, the largest reported in clinical isolates. Despite this extensive genomic change, the strain maintained robust replication capacity and marked fusogenicity in vitro . We report, for the first time in clinical isolates, a massive genomic rearrangement in MPXV that does not impair viral replicability. This finding represents an example of genomic plasticity and provides a rare but noteworthy resource for future studies. Taken together, when performing genomic analyses of MPXV, aberrant genomic rearrangements should also be carefully considered alongside single-base substitutions.
- 5 February 2026
- Published by Microbiology Society in Journal of General Virology
- Vol. 107 (2) , 002215
Open AccessIdentification of an extremely large-scale genomic rearrangement in the Mpox virus while retaining replicative capacity
Understanding the genomic diversity of the Mpox (formerly known as ‘monkeypox’) virus (MPXV) is important for monitoring viral evolution and dissemination. We encountered three clinical cases in our hospital during the outbreak period of Mpox in 2023 in Japan. The present study aims to report the largest genomic rearrangement observed to date in one of the clinical isolates and to demonstrate its viability in cell culture. Whole-genome sequencing and digital PCR were used to characterize the viral genomes. Viral isolation, microscopic observation and growth kinetics in Vero cells were performed to confirm viral replication. All three patients were men living with human immunodeficiency virus (HIV) and presented typical Mpox symptoms, such as rash, fever and pustules on the body surfaces, including near the genitals. Virus isolation was successful in all three cases. All viral strains belonged to clade IIb, lineage C.1. Notably, one strain exhibited a large-scale genomic rearrangement: a 5.5 kb deletion at the left variable region replaced by a 30.5 kb inverted sequence, the largest reported in clinical isolates. Despite this extensive genomic change, the strain maintained robust replication capacity and marked fusogenicity in vitro . We report, for the first time in clinical isolates, a massive genomic rearrangement in MPXV that does not impair viral replicability. This finding represents an example of genomic plasticity and provides a rare but noteworthy resource for future studies. Taken together, when performing genomic analyses of MPXV, aberrant genomic rearrangements should also be carefully considered alongside single-base substitutions.
- 9 December 2024
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (3) , 102581
Gastrointestinal bacteria growth inhibition by a toilet sanitary good for disaster shelter
- 9 December 2024
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (3) , 102581
Gastrointestinal bacteria growth inhibition by a toilet sanitary good for disaster shelter
- Open Access
- 7 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Altered genomic methylation promotes Staphylococcus aureus persistence in hospital environment
Staphylococcus aureus can cause outbreaks and becomes multi-drug resistant through gene mutations and acquiring resistance genes. However, why S. aureus easily adapts to hospital environments, promoting resistance and recurrent infections, remains unknown. Here we show that a specific S. aureus lineage evolved from a clone that expresses the accessory gene regulator (Agr) system to subclones that reversibly suppressed Agr and caused an outbreak in the hospital setting. S. aureus with flexible Agr regulation shows increased ability to acquire antibiotic-resistant plasmids, escape host immunity, and colonize mice. Bacteria with flexible Agr regulation shows altered cytosine genomic methylation, including the decreased 5mC methylation in transcriptional regulator genes (pcrA and rpsD), compared to strains with normal Agr expression patterns. In this work, we discover how altered genomic methylation promotes flexible Agr regulation which is associated with persistent pathogen colonization in the hospital environment.
- 7 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Open AccessAltered genomic methylation promotes Staphylococcus aureus persistence in hospital environment
Staphylococcus aureus can cause outbreaks and becomes multi-drug resistant through gene mutations and acquiring resistance genes. However, why S. aureus easily adapts to hospital environments, promoting resistance and recurrent infections, remains unknown. Here we show that a specific S. aureus lineage evolved from a clone that expresses the accessory gene regulator (Agr) system to subclones that reversibly suppressed Agr and caused an outbreak in the hospital setting. S. aureus with flexible Agr regulation shows increased ability to acquire antibiotic-resistant plasmids, escape host immunity, and colonize mice. Bacteria with flexible Agr regulation shows altered cytosine genomic methylation, including the decreased 5mC methylation in transcriptional regulator genes (pcrA and rpsD), compared to strains with normal Agr expression patterns. In this work, we discover how altered genomic methylation promotes flexible Agr regulation which is associated with persistent pathogen colonization in the hospital environment.
- Open Access
- 29 April 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-11
Dynamic diversity of SARS-CoV-2 genetic mutations in a lung transplantation patient with persistent COVID-19
Numerous SARS-CoV-2 variant strains with altered characteristics have emerged since the onset of the COVID-19 pandemic. Remdesivir (RDV), a ribonucleotide analogue inhibitor of viral RNA polymerase, has become a valuable therapeutic agent. However, immunosuppressed hosts may respond inadequately to RDV and develop chronic persistent infections. A patient with respiratory failure caused by interstitial pneumonia, who had undergone transplantation of the left lung, developed COVID-19 caused by Omicron BA.5 strain with persistent chronic viral shedding, showing viral fusogenicity. Genome-wide sequencing analyses revealed the occurrence of several viral mutations after RDV treatment, followed by dynamic changes in the viral populations. The C799F mutation in nsp12 was found to play a pivotal role in conferring RDV resistance, preventing RDV-triphosphate from entering the active site of RNA-dependent RNA polymerase. The occurrence of diverse mutations is a characteristic of SARS-CoV-2, which mutates frequently. Herein, we describe the clinical case of an immunosuppressed host in whom inadequate treatment resulted in highly diverse SARS-CoV-2 mutations that threatened the patient’s health due to the development of drug-resistant variants.
- 29 April 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-11
Open AccessDynamic diversity of SARS-CoV-2 genetic mutations in a lung transplantation patient with persistent COVID-19
Numerous SARS-CoV-2 variant strains with altered characteristics have emerged since the onset of the COVID-19 pandemic. Remdesivir (RDV), a ribonucleotide analogue inhibitor of viral RNA polymerase, has become a valuable therapeutic agent. However, immunosuppressed hosts may respond inadequately to RDV and develop chronic persistent infections. A patient with respiratory failure caused by interstitial pneumonia, who had undergone transplantation of the left lung, developed COVID-19 caused by Omicron BA.5 strain with persistent chronic viral shedding, showing viral fusogenicity. Genome-wide sequencing analyses revealed the occurrence of several viral mutations after RDV treatment, followed by dynamic changes in the viral populations. The C799F mutation in nsp12 was found to play a pivotal role in conferring RDV resistance, preventing RDV-triphosphate from entering the active site of RNA-dependent RNA polymerase. The occurrence of diverse mutations is a characteristic of SARS-CoV-2, which mutates frequently. Herein, we describe the clinical case of an immunosuppressed host in whom inadequate treatment resulted in highly diverse SARS-CoV-2 mutations that threatened the patient’s health due to the development of drug-resistant variants.
- Open Access
- 22 December 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (52)
Infectious virus shedding duration reflects secretory IgA antibody response latency after SARS-CoV-2 infection
Infectious virus shedding from individuals infected with severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is used to estimate human-to-human transmission risk. Control of SARS-CoV-2 transmission requires identifying the immune correlates that protect infectious virus shedding. Mucosal immunity prevents infection by SARS-CoV-2, which replicates in the respiratory epithelium and spreads rapidly to other hosts. However, whether mucosal immunity prevents the shedding of the infectious virus in SARS-CoV-2-infected individuals is unknown. We examined the relationship between viral RNA shedding dynamics, duration of infectious virus shedding, and mucosal antibody responses during SARS-CoV-2 infection. Anti-spike secretory IgA antibodies (S-IgA) reduced viral RNA load and infectivity more than anti-spike IgG/IgA antibodies in infected nasopharyngeal samples. Compared with the IgG/IgA response, the anti-spike S-IgA post-infection responses affected the viral RNA shedding dynamics and predicted the duration of infectious virus shedding regardless of the immune history. These findings highlight the importance of anti-spike S-IgA responses in individuals infected with SARS-CoV-2 for preventing infectious virus shedding and SARS-CoV-2 transmission. Developing medical countermeasures to shorten S-IgA response time may help control human-to-human transmission of SARS-CoV-2 infection and prevent future respiratory virus pandemics.
- 22 December 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (52)
Open AccessInfectious virus shedding duration reflects secretory IgA antibody response latency after SARS-CoV-2 infection
Infectious virus shedding from individuals infected with severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is used to estimate human-to-human transmission risk. Control of SARS-CoV-2 transmission requires identifying the immune correlates that protect infectious virus shedding. Mucosal immunity prevents infection by SARS-CoV-2, which replicates in the respiratory epithelium and spreads rapidly to other hosts. However, whether mucosal immunity prevents the shedding of the infectious virus in SARS-CoV-2-infected individuals is unknown. We examined the relationship between viral RNA shedding dynamics, duration of infectious virus shedding, and mucosal antibody responses during SARS-CoV-2 infection. Anti-spike secretory IgA antibodies (S-IgA) reduced viral RNA load and infectivity more than anti-spike IgG/IgA antibodies in infected nasopharyngeal samples. Compared with the IgG/IgA response, the anti-spike S-IgA post-infection responses affected the viral RNA shedding dynamics and predicted the duration of infectious virus shedding regardless of the immune history. These findings highlight the importance of anti-spike S-IgA responses in individuals infected with SARS-CoV-2 for preventing infectious virus shedding and SARS-CoV-2 transmission. Developing medical countermeasures to shorten S-IgA response time may help control human-to-human transmission of SARS-CoV-2 infection and prevent future respiratory virus pandemics.
- 20 July 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (11) , 1483-1488
Antibody responses and SARS-CoV-2 infection after BNT162b2 mRNA booster vaccination among healthcare workers in Japan
- 20 July 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (11) , 1483-1488
Antibody responses and SARS-CoV-2 infection after BNT162b2 mRNA booster vaccination among healthcare workers in Japan
- Open Access
- 6 March 2022
- Published by Wiley in Respirology
- Vol. 27 (5) , 370-371
Tolerability of prone positioning in non‐intubated patients with hypoxaemia due to COVID‐19‐related pneumonia
- 6 March 2022
- Published by Wiley in Respirology
- Vol. 27 (5) , 370-371
Open AccessTolerability of prone positioning in non‐intubated patients with hypoxaemia due to COVID‐19‐related pneumonia
- Open Access
- 1 March 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (6) , 791-796
Adverse effect investigation using application software after vaccination against SARS-CoV-2 for healthcare workers
- 1 March 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (6) , 791-796
Open AccessAdverse effect investigation using application software after vaccination against SARS-CoV-2 for healthcare workers